Diabetes in Canada: Direct Medical Costs of Major Macrovascular Complications

O’Brien, Judith A.; Caro, Ingrid; Getsios, Denis; Jaime, J.

doi:10.1046/j.1524-4733.2001.43017.x

Cited by 25 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For those who developed diabetes, the cost estimates for its management were based on previously developed cost profiles for each of the complication pathways considered in the diabetes submodel. 193,194 For each complication, the average direct cost of managing such an event from the acute phase until death was estimated. Costs included in these calculations included hospitalisation costs, home healthcare services, outpatient services, nursing home care, laboratory tests, drugs, emergency room visits and diagnostic and therapeutic procedures.…”

Section: Costsmentioning

confidence: 99%

Screening for type 2 diabetes: literature review and economic modelling

Waugh¹,

Scotland²,

McNamee³

et al. 2007

Health Technol Assess

243

194

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

Section: Costsmentioning

confidence: 99%

Screening for type 2 diabetes: literature review and economic modelling

Waugh¹,

Scotland²,

McNamee³

et al. 2007

Health Technol Assess

243

194

View full text Add to dashboard Cite

show abstract

“…For example, if a new drug is more expensive but reduces the frequency of hyperglycemia then its economic assessment must address costs at a more detailed level. Building on our previously published work on the Canadian costs of major macrovascular complications of diabetes [12], the aim of this paper is to provide key pieces of that complex economic puzzle. This paper presents updated Canadian-specific cost information for macrovascular complications and new information on microvascular complications.…”

Section: Introductionmentioning

confidence: 99%

Cost of managing complications resulting from type 2 diabetes mellitus in Canada

O’Brien¹,

Patrick²,

Jaime

2003

BMC Health Serv Res

100

View full text Add to dashboard Cite

Background: Decision makers need to have Canadian-specific cost information in order to develop an accurate picture of diabetes management. The objective of this study is to estimate direct medical costs of managing complications of diabetes. Complication costs were estimated by applying unit costs to typical resource use profiles. For each complication, the event costs refer to those associated with the acute episode and subsequent care in the first year. State costs are the annual costs of continued management. Data were obtained from many Canadian sources, including the Ontario Case Cost Project, physician and laboratory fee schedules, formularies, reports, and literature. All costs are expressed in 2000 Canadian dollars.

show abstract

“…Simona de Portu (1) , Enrica Menditto (1) , Lorenzo G. Mantovani (1) ABSTRACT Introduction: cardiovascular diseases (CVD) are the major component of premature mortality, generate disability and are a relevant source of cost. The growing incidence of CVD is associated with lifestyle and other modifiable risk factors.…”

Section: Valutazione Economica Dello Studio Cardsmentioning

confidence: 99%

“…Tale peso è attribuibile a due circostanze: la gestione del diabete in se stesso ed il trattamento delle sue complicanze [1,2]. Il diabete mellito è una malattia molto diffusa associata ad un incremento del rischio di malattie concomitanti e di morte.…”

Section: Introduzioneunclassified

Valutazione economica dello studio CARDS

Portu

Menditto

Mantovani

2007

View full text Add to dashboard Cite

Il presente articolo è già stato pubblicato sulla rivista "Farmeconomia e percorsi terapeutici" nel terzo numero del 2006. Per completezza lo riportiamo anche in questo supplemento dedicato al ruolo delle statine, e in particolare di atorvastatina, nella riduzione del rischio cardiovascolare.ipertensione, dislipidemia e problemi della coagulazione [5]. Inoltre, nei pazienti diabetici, aumenta il rischio di malattie coronariche e cerebrovascolari. L'infarto acuto del miocardio, ad esempio, si manifesta con una frequenza da due a tre volte maggiore nei soggetti diabetici rispetto ai non diabetici, mentre il rischio di ictus e di sviluppare malattie vascolari periferiche è ancora più elevato.L'associazione americana per il diabete ha stimato che negli USA nel 2002 globalmente sono stati investiti 132 miliardi di dollari, dove il 70% è da attribuirsi a costi diretti.Per quanto concerne l'Europa lo studio CODE (Cost of Diabetes in Europe-type 2) è nato con lo scopo di stimare in otto nazioni (Belgio, Francia, Germania, Gran Bretagna, Italia, Olanda, Spagna, Svezia) i costi della gestione di pazienti con diabete di tipo 2, dal quale è emerso chiaramente che il diabete richiede cospicue INTRODUZIONEIl peso economico del diabete è sicuramente rilevante per la società. Tale peso è attribuibile a due circostanze: la gestione del diabete in se stesso ed il trattamento delle sue complicanze [1,2]. Il diabete mellito è una malattia molto diffusa associata ad un incremento del rischio di malattie concomitanti e di morte. Si stima che in Europa siano affetti da diabete mellito più di 18,5 milioni di persone [3], mentre la prevalenza di diabete diagnosticato in Italia è del 3% circa [4]. Da un recente studio condotto in Italia risulta che l'incidenza del diabete mellito è di 2,2 per 1000 persone per anno (gli uomini 2,0 e le donne 2,4) [4].Per quanto riguarda la manifestazione delle complicanze associate alla malattia, esistono numerosi fattori di rischio che contribuiscono allo sviluppo di malattie macrovascolari in soggetti affetti da diabete mellito, tra cui iperglicemia, ABSTRACT Introduction: cardiovascular diseases (CVD) are the major component of premature mortality, generate disability and are a relevant source of cost. The growing incidence of CVD is associated with lifestyle and other modifiable risk factors. Prevention and preclinical detection of CVD reduce morbidity and mortality. Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease. Objective: the aim of the study was to evaluate the health economic consequence of medical therapy with atorvastatin for primary prevention of major cardiovascular events in patients with type 2 diabetes in Italy. Materials and method: in order to reach our objective we drew clinical information from the CARDS study. This economic evaluation was carried out conducting a cost/effectiveness analysis from the perspective of National Health Service (NHS). The analysis was applied to a time horizon in conformity with the observational period adopted in...

show abstract

Diabetes in Canada: Direct Medical Costs of Major Macrovascular Complications

Cited by 25 publications

References 22 publications

Screening for type 2 diabetes: literature review and economic modelling

Screening for type 2 diabetes: literature review and economic modelling

Cost of managing complications resulting from type 2 diabetes mellitus in Canada

Valutazione economica dello studio CARDS

Contact Info

Product

Resources

About